Modern Action logo
IssuesBillsBriefingNewsletterAbout
Donate
Donate
Modern Action

Navigation

Menu

01HomeFront page→02IssuesActive issue pages→03BillsLegislation index→04BriefingDaily context→05NewsletterWeekly Watchlist→06AboutMission and team→07DonateSupport the work→

Account

Sign In→Get Started→
Modern Action

Find the bills behind the news, understand what Congress can do, and contact your representatives with a specific message.

Platform

  • Contact Congress
  • Write to Congress
  • Browse Bills
  • Bill Explainers
  • Track Bills

Resources

  • Find My Representatives
  • Contact My Representatives
  • How to Contact Representatives
  • Does Contacting Congress Work?
  • Newsletter

Support

  • About
  • Contact Us
  • Press
  • Accessibility

Legal

  • Privacy Policy
  • Terms of Service
  • Cookie Policy
  • Accessibility

Stay informed about legislation

Get weekly updates on important bills and how to take action.

© 2026 Modern Action. All rights reserved.

Made with ❤️ for democracy
All systems operational

Contact Congress about H.R. 2450: Prescription Drug Transparency and Affordability Act

PBMs would have to give employer health plans detailed reports on drug prices, rebates, fees, and payment spreads. People in those plans could ask for summaries and some details about their own prescriptions. The bill also sets privacy rules and steep penalties for missing or false reports.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Prescription Drug Transparency and Affordability Act is a House bill in committee. The latest recorded action: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Latest action on H.R. 2450: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Who this affects: This bill mainly affects employer health plans, the companies they hire to manage drug benefits, and the workers and family members covered by those plans. It also reaches insurers, affiliated pharmacies, rebate middlemen, and other companies tied to the prescription drug supply chain when they are part of the reporting process.

Why this matters: Prescription drug costs can be hard for employers and patients to understand because key payments often stay hidden. This bill tries to expose more of that money flow, especially the gap between what a plan pays a PBM and what the PBM pays a pharmacy. That could help plans judge whether they are getting fair value and help patients understand some of the costs behind their prescriptions. But the bill does not promise lower prices, lower premiums, or lower copays, because those results would depend on how companies respond.

Key provisions in H.R. 2450

  • The bill covers employer group health plans and group health insurance. It applies under three major federal laws: the Public Health Service Act, ERISA, and the Internal Revenue Code.
  • The rules would not start right away. They would kick in for plan years that begin 30 months after the law is passed, and they would apply to new, renewed, or extended PBM contracts and contracts with other covered entities.
  • PBMs would have to send plans detailed reports at least twice a year. If a plan asks, they would have to report every quarter and include drug-level and drug-class data on spending, prices, rebates, fees, and what patients paid themselves.
  • Very expensive drugs would get extra reporting. That includes drugs with more than $10,000 in gross spending in a plan year and drugs that rank in the top 50 by spending.
  • Plans and PBMs would have to explain plan features that shape how people get drugs. That includes tools like prior authorization, step therapy, and steering people to mail-order, specialty, or affiliated pharmacies, plus data on how much those pharmacies are used.

How Modern Action helps you take action on H.R. 2450

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about H.R. 2450

What is H.R. 2450?
PBMs would have to give employer health plans detailed reports on drug prices, rebates, fees, and payment spreads. People in those plans could ask for summaries and some details about their own prescriptions. The bill also sets privacy rules and steep penalties for missing or false reports.
How do I support or oppose H.R. 2450?
Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.
Who should I contact about H.R. 2450?
Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.
Can Modern Action explain H.R. 2450 before I act?
Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.

Keep acting on Modern Action

More ways to act on this issue

Compare the broader issue and related bills without leaving Modern Action.

Related issues

  • Contact your reps on PBM Rebates, Spread Pricing, and Pharmacy PaymentsPBMs would disclose or pass through rebates, stop hidden spread pricing, limit clawbacks, delink compensation from drug prices, report pharmacy steering, and face audits or penalties.
  • Contact your reps on Employer Health Plan Data and PBM TransparencyEmployer and plan-sponsor access to claims, pharmacy, rebate, fee, and vendor compensation data; anti-gag clauses; audit rights; PBM spread pricing and rebate pass-through reporting; fiduciary duties; and penalties for vendors that block data.

Related bills

  • Take action on H.R. 6703: Lower Health Care Premiums for All Americans Act
  • Take action on H.R. 7148: Consolidated Appropriations Act, 2026
  • Take action on S. 891: Bipartisan Health Care Act
  • Take action on H.R. 1768: Lower Costs for Everyday Americans Act
  • Take action on H.R. 2880: Protecting Patients Against PBM Abuses Act
  • Take action on H.R. 1613: Drug Price Transparency in Medicaid Act of 2023
  • Take action on H.R. 9393: Lower Costs, More Transparency Act of 2026
  • Take action on S. 1339: Pharmacy Benefit Manager Reform Act